NuScale Power Stock Is Plunging: What's Causing the Decline

NuScale Power’s first commercial SMRs are now expected in the early 2030s after repeated delays, while the stock trades just above $10 versus a $53.43 peak on Oct. 15, 2025. The company faces inflation-driven cost pressure, intense competition, class action lawsuits, and heavy insider selling, even as analysts still model revenue growth to $56 million in 2026 and $173 million in 2027. Valuation remains stretched at 63x this year’s sales, limiting near-term upside.

Analysis

SMR is transitioning from a story stock to a financing-and-execution problem. The market is discounting not just timing slippage, but the compounding effect of every delay: a later revenue ramp means more dilution risk, higher cumulative burn, and a weaker ability to outspend better-capitalized competitors on licensing, engineering, and regulatory throughput. In that setup, the stock’s downside is less about one missed milestone and more about a prolonged period where investors pay a premium multiple for a business that still behaves like an option on commercialization.

The second-order winner is not necessarily the largest reactor vendor, but whoever can monetize the “picks and shovels” layer around the buildout. FLR’s role is more nuanced than a simple customer-supplier link: if SMR projects slip, the contractor may still preserve economics through engineering work, but it loses the operating leverage narrative that would have accompanied a faster rollout. OKLO benefits from the same thematic tailwind while also inheriting the market’s appetite for smaller, faster-to-deploy solutions; however, that also means it becomes the next vehicle for the same skepticism if timelines stretch or permitting surprises emerge.

The core catalyst path is binary and long-dated: a credible de-risking event over the next 6-18 months could stabilize the tape, but absent first-commercial visibility, valuation is vulnerable to multiple compression whenever rate expectations rise or growth sentiment weakens. The most important tell is not headline partnership count; it is whether contracted work converts into tangible milestone receipts and whether capital markets remain open without punitive dilution. On a years-long horizon, the thesis only works if the company can prove it is a technology platform rather than a perpetual pre-revenue funding story.

Key Decisions for Investors

• Avoid initiating new long SMR exposure until a credible commercialization or financing de-risking event; use the next 6-12 months as a wait-and-see window rather than paying for optionality at a rich multiple.
• For existing holders, consider a covered-call overlay on SMR into strength over the next 1-3 months to monetize high implied volatility while capping upside in a name where valuation is still fragile.
• Relative-value pair: long FLR / short SMR over 3-6 months if you want exposure to nuclear buildout without paying for execution risk; FLR captures project activity earlier and has a more diversified earnings base.
• Speculative pair: long OKLO / short SMR on a 6-12 month horizon if you believe the market keeps rewarding faster-permitting, smaller-scale reactor concepts over slower commercialization paths; keep size modest because both are narrative-driven.
• Set a tactical alert on any announcement that pulls first revenue-bearing deployment meaningfully forward; that would be the first credible trigger to cover shorts or reassess a bearish stance.